The 84th API China & CHINA-PHARM IN QINGDAO

DATE: Jun. 9-11, 2020

With the continuous evaluation of the consistency of generic drugs and the implementation of the policy, pharmaceutical companies independently improve their product quality and take responsibility for their own products, which also greatly enhances the subjective initiative of API companies. China's API market has already burst into new vitality, major pharmaceutical companies brought their traditional advantages and the latest research and development of new products to gather in Qingdao, with more than 1,000 Chinese outstanding API companies together in Hall S4 and Hall S5.

NCMC is actively participating with products like inorganic iodides, lithium compounds, special esters, amines and nitriles and other pharmaceutical raw materials and intermediates. Under the pessimistic economic environment and the impact of Covid-19, we fully exchange views with suppliers and customers, plan for the industry prospects, and make efforts to better serve the market.

There were limited exhibitors and visitors this time, and the entire pharmaceutical industry was also greatly affected by the epidemic. Generally export orders are limited, and domestic orders of commonly used pharmaceutical products are stable. Chemical and pharmaceutical companies are basically mature and stable, while there are new manufacturers in biopharmaceutical (protein, peptide, vaccine, biomacromolecule) companies.

NCMC is looking forward to meeting with all friends in API Nanjing at H2 2020!